JOP20140141B1 - استخدام 3،2- ثنائي هيدروإيميدازول-[2،1-c] كونازولينات مستبدلة لمعالجة الاورام الليمفاوية - Google Patents

استخدام 3،2- ثنائي هيدروإيميدازول-[2،1-c] كونازولينات مستبدلة لمعالجة الاورام الليمفاوية

Info

Publication number
JOP20140141B1
JOP20140141B1 JOP/2014/0141A JOP20140141A JOP20140141B1 JO P20140141 B1 JOP20140141 B1 JO P20140141B1 JO P20140141 A JOP20140141 A JO P20140141A JO P20140141 B1 JOP20140141 B1 JO P20140141B1
Authority
JO
Jordan
Prior art keywords
dihydroimidazo
quinazolines
substituted
treating lymphomas
lymphomas
Prior art date
Application number
JOP/2014/0141A
Other languages
English (en)
Inventor
Haike Katja
Paul Juliane
Ningshu Liu Dr
Antje Margret Wengner Dr
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Application granted granted Critical
Publication of JOP20140141B1 publication Critical patent/JOP20140141B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

يتعلق الاختراع الحالي بما يلي:
JOP/2014/0141A 2013-04-08 2014-04-06 استخدام 3،2- ثنائي هيدروإيميدازول-[2،1-c] كونازولينات مستبدلة لمعالجة الاورام الليمفاوية JOP20140141B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13162710 2013-04-08
EP13184240 2013-09-13

Publications (1)

Publication Number Publication Date
JOP20140141B1 true JOP20140141B1 (ar) 2021-08-17

Family

ID=50439383

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0141A JOP20140141B1 (ar) 2013-04-08 2014-04-06 استخدام 3،2- ثنائي هيدروإيميدازول-[2،1-c] كونازولينات مستبدلة لمعالجة الاورام الليمفاوية

Country Status (27)

Country Link
US (2) US9999623B2 (ar)
EP (1) EP2983669B1 (ar)
JP (1) JP6368353B2 (ar)
KR (1) KR102304108B1 (ar)
CN (1) CN105263497B (ar)
AP (1) AP2015008750A0 (ar)
AU (1) AU2014253348B2 (ar)
BR (1) BR112015025304B1 (ar)
CA (1) CA2908776C (ar)
CL (1) CL2015002978A1 (ar)
CR (1) CR20150523A (ar)
CU (1) CU24400B1 (ar)
DO (1) DOP2015000256A (ar)
EA (2) EA037577B1 (ar)
ES (1) ES2708350T3 (ar)
IL (1) IL241543B (ar)
JO (1) JOP20140141B1 (ar)
MX (1) MX2015014171A (ar)
MY (1) MY192626A (ar)
NI (1) NI201500148A (ar)
PE (1) PE20151780A1 (ar)
PH (1) PH12015502317A1 (ar)
SG (2) SG10201710539QA (ar)
TN (1) TN2015000452A1 (ar)
TW (2) TWI689307B (ar)
UA (2) UA119537C2 (ar)
WO (1) WO2014166820A1 (ar)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
WO2015082376A2 (en) * 2013-12-03 2015-06-11 Bayer Pharma Aktiengesellschaft Use of pi3k-inhibitors
WO2015082378A1 (en) 2013-12-03 2015-06-11 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
CN105017256A (zh) 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
WO2016087488A1 (en) * 2014-12-03 2016-06-09 Bayer Pharma Aktiengesellschaft Administration regime for aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives
WO2016087490A1 (en) * 2014-12-03 2016-06-09 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
EA201791974A1 (ru) 2015-03-09 2018-05-31 Байер Фарма Акциенгезельшафт Комбинации, содержащие замещенный 2,3-дигидроимидазо[1,2-с]хиназолин
US9717745B2 (en) 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
IL293821A (en) 2015-07-02 2022-08-01 Acerta Pharma Bv Solid forms and formulations of (S)-4-(8-amino-3-(1-(but-2-aminoyl)pyrrolidine-2-yl)imidazo[5,1-yl]pyrazin-1-yl)-en- (pyridine-2-yl)benzamide
TN2018000272A1 (en) * 2016-02-01 2020-01-16 Bayer Pharma AG Copanlisib biomarkers
TN2018000271A1 (en) * 2016-02-01 2020-01-16 Bayer Pharma AG Copanlisib biomarkers.
WO2017153220A1 (en) 2016-03-08 2017-09-14 Bayer Pharma Aktiengesellschaft 2—amino—n— [7—methoxy—2, 3-dihydroimidazo-[1, 2-c] quinazolin-5-yl] pyrimidine—5—carboxamides
EP3219329A1 (en) * 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
US10689378B2 (en) * 2016-06-20 2020-06-23 Novartis Ag Triazolopyridine compounds and uses thereof
JP2019524872A (ja) * 2016-06-20 2019-09-05 ノバルティス アーゲー 癌の治療に有用なイミダゾピリミジン化合物
WO2018054782A1 (en) * 2016-09-23 2018-03-29 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
EP3626239B1 (en) 2017-05-18 2024-07-03 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Ezh2 inhibitor combined with btk inhibitor for treating tumor
CA3068324A1 (en) 2017-06-28 2019-01-03 Bayer Consumer Care Ag Combination of a pi3k-inhibitor with an androgen receptor antagonist
MX2020002875A (es) 2017-09-13 2020-07-22 Guangdong Oppo Mobile Telecommunications Corp Ltd Metodo de procesamiento de datos, dispositivo terminal y dispositivo de red.
TW201922256A (zh) 2017-10-27 2019-06-16 中國大陸商浙江導明醫藥科技有限公司 治療淋巴樣惡性疾病之方法
CA3157789A1 (en) * 2019-10-15 2021-04-22 Bayer Aktiengesellschaft 2-methyl-aza-quinazolines
WO2022199373A1 (zh) * 2021-03-26 2022-09-29 上海璎黎药业有限公司 一种喹唑啉化合物及药物组合物的应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1400959A (en) 1919-04-26 1921-12-20 Ste Chim Usines Rhone Process and apparatus for carrying out chemical reactions by catalysis
US1364099A (en) 1919-09-10 1921-01-04 Flannery Bolt Co Staybolt structure for boilers
US1400975A (en) 1920-10-11 1921-12-20 Page Henry Benjiman Dirigible headlight for motor-vehicles
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
JP2003277383A (ja) 2002-03-14 2003-10-02 Bayer Ag 光学活性ピリジン誘導体およびそれを含む医薬
WO2004029055A1 (en) 2002-09-30 2004-04-08 Bayer Pharmaceuticals Corporation Fused azole-pyrimidine derivatives
AR064106A1 (es) 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
CA2713388C (en) 2008-01-14 2016-03-29 William Scott Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EA201201414A8 (ru) 2010-04-16 2013-12-30 Байер Интеллектчуал Проперти Гмбх КОМБИНАЦИИ, СОДЕРЖАЩИЕ ЗАМЕЩЕННЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНЫ
CA2797398C (en) 2010-05-14 2017-01-24 Lg Electronics Inc. Method for allocating resources in a wireless communication system and a device for the same
UA113280C2 (xx) * 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
JP5790016B2 (ja) 2011-02-18 2015-10-07 コベルコ建機株式会社 ハイブリッド建設機械
MX352844B (es) * 2011-02-28 2017-12-11 Calitor Sciences Llc Compuestos de quinolina sustituidos y metodos de uso.
US20140213630A1 (en) 2011-03-08 2014-07-31 Thomas Diacovo Methods and pharmaceutical compositions for treating lymphoid malignancy
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
ES2624981T3 (es) * 2011-07-01 2017-07-18 Dana-Farber Cancer Institute, Inc. Descubrimiento de una mutación somática en el gen MYD88 en linfoma linfoplasmocitario
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
US8993891B2 (en) 2012-06-28 2015-03-31 Thomas & Betts International, Inc. Lift and pivot grommet
CN105934256B (zh) 2013-12-03 2019-12-27 拜耳制药股份公司 Pi3k-抑制剂的组合产品
EP3018131A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
WO2016142313A1 (en) 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
EA201791974A1 (ru) 2015-03-09 2018-05-31 Байер Фарма Акциенгезельшафт Комбинации, содержащие замещенный 2,3-дигидроимидазо[1,2-с]хиназолин

Also Published As

Publication number Publication date
NZ712033A (en) 2021-03-26
EA031493B1 (ru) 2019-01-31
ES2708350T3 (es) 2019-04-09
HK1220121A1 (zh) 2017-04-28
EA201792650A1 (ru) 2018-04-30
CU20150140A7 (es) 2016-10-28
BR112015025304A2 (pt) 2017-07-18
US9999623B2 (en) 2018-06-19
BR112015025304B1 (pt) 2022-09-27
EP2983669A1 (en) 2016-02-17
CL2015002978A1 (es) 2016-04-15
EA037577B1 (ru) 2021-04-16
MX2015014171A (es) 2015-12-16
AU2014253348B2 (en) 2019-05-23
AU2014253348A1 (en) 2015-10-08
UA122822C2 (uk) 2021-01-06
TWI675663B (zh) 2019-11-01
JP2016515601A (ja) 2016-05-30
EA031493B9 (ru) 2019-12-18
CU24400B1 (es) 2019-04-04
SG10201710539QA (en) 2018-01-30
WO2014166820A1 (en) 2014-10-16
UA119537C2 (uk) 2019-07-10
PE20151780A1 (es) 2015-12-20
SG11201507265XA (en) 2015-10-29
TWI689307B (zh) 2020-04-01
US20160058770A1 (en) 2016-03-03
JP6368353B2 (ja) 2018-08-01
IL241543B (en) 2019-08-29
CA2908776C (en) 2021-08-10
PH12015502317A1 (en) 2016-02-10
CR20150523A (es) 2016-01-29
KR102304108B1 (ko) 2021-09-23
KR20150138858A (ko) 2015-12-10
TW201924690A (zh) 2019-07-01
TW201517909A (zh) 2015-05-16
MY192626A (en) 2022-08-29
EP2983669B1 (en) 2018-10-24
NI201500148A (es) 2015-11-30
CN105263497B (zh) 2019-04-30
TN2015000452A1 (en) 2017-04-06
EA201591932A1 (ru) 2016-04-29
CN105263497A (zh) 2016-01-20
DOP2015000256A (es) 2015-12-31
US10226469B2 (en) 2019-03-12
CA2908776A1 (en) 2014-10-16
US20180193349A1 (en) 2018-07-12
AP2015008750A0 (en) 2015-09-30

Similar Documents

Publication Publication Date Title
IL241543B (en) Use of converted 2, 3-dihydroimidazo[1, 2-c] quinazolines for the treatment of lymphoid tissue metastasis
PH12019501321B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
IN2015DN00127A (ar)
IL243883A0 (en) Methods for treating sporadic meiosis of the body as a whole
EP2968311A4 (en) OXAZOLO [5,4-C] CHINOLIN-2-ON COMPOUNDS AS BROMODOMENA INHIBITORS
ZA201505011B (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
PH12016501232A1 (en) Pyrazolo[1,5-a]pyridine derivatives and methods of their use
EP2986140A4 (en) COMPOSITIONS, PROCESSES AND KIT FOR TREATMENT OF PETS
IL246252A0 (en) Diaminopyrimidyl derivative compounds, their compositions and methods of treatment
IN2015DN00438A (ar)
PT3016656T (pt) Compostos bicíclicos úteis para o tratamento de doenças causadas por retrovírus
MY189912A (en) Substituted xanthines and methods of use thereof
EP2967049A4 (en) Methods, compounds, and compositions for the treatment of angiotensin-related diseases
PH12016500643B1 (en) NEW OCTAHYDRO-CYCLOBUTA [1,2-c;3,4-c'] DIPYRROL-2-YL
IL254168A0 (en) Use of 3,2-dihydroimidazo[2,1-c]converted quinazolines
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
MX360774B (es) Antagonistas de progesterona.
MX2015009818A (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerosis multiple.
SI2981303T1 (sl) Sestavek polnila za zdravljenje lipoatrofije
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
EA201690716A1 (ru) ПИРИДО[2,3-d]ПИРИМИДИН-4-ОНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ТАНКИРАЗЫ
IN2014DN11078A (ar)
EP3089745A4 (en) Compounds, compositions, and methods for the treatment of cancers
SG10201908881PA (en) Fused bicyclic compounds for the treatment of disease
GEP201706795B (en) Hexahydrofuropyrroles as pde1 inhibitors